Novel Immunotherapy for Metastatic Bladder Cancer Using Vaccine of Human Interleukin-2 Surface-modified MB 49 Cells

Objective To develop a novel protein-anchor technology to immobilize human interleukin-2 on tumor cells to induce antitumor immunity. Methods Interleukin-2 surface-modified MB49 cells were prepared as a vaccine. Subcutaneous and pulmonary metastatic mouse models of MB49 bladder cancer were used to e...

Full description

Saved in:
Bibliographic Details
Published in:Urology (Ridgewood, N.J.) N.J.), 2011-09, Vol.78 (3), p.722.e1-722.e6
Main Authors: Zhang, Xinji, Shi, Xiaojun, Li, Jinlong, Hu, Zhiming, Guo, Fangfang, Huang, Xiao, Zhang, Zhehuan, Sun, Pengyu, Jing, Yuming, Gao, Jimin, Tan, Wanlong
Format: Article
Language:English
Subjects:
Animals
Cancer Vaccines - therapeutic use
Cell Line, Tumor
Cytotoxicity, Immunologic
Female
Humans
Immunotherapy
Interleukin-2 - immunology
Lung Neoplasms - immunology
Lung Neoplasms - secondary
Lung Neoplasms - therapy
Mice
Mice, Inbred C57BL
Recombinant Fusion Proteins
Streptavidin
T-Lymphocytes - immunology
Urinary Bladder Neoplasms - immunology
Urinary Bladder Neoplasms - pathology
Urinary Bladder Neoplasms - therapy
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To develop a novel protein-anchor technology to immobilize human interleukin-2 on tumor cells to induce antitumor immunity. Methods Interleukin-2 surface-modified MB49 cells were prepared as a vaccine. Subcutaneous and pulmonary metastatic mouse models of MB49 bladder cancer were used to evaluate the antitumor efficiency of the vaccine. Immunohistochemistry, flow cytometric, and cytotoxic T-lymphocyte assay were performed to assess the proportion and cytotoxicity of the T lymphocytes. Results The IL-2 surface-modified MB49 cell vaccine inhibited tumor growth and extended the survival of the mice, and the vaccine-cured mice effectively resisted the second MB49 but not the RM-1 prostate cancer cell challenge. Furthermore, more cytotoxicity on the MB49 cells and more CD4-positive, CD8-positive T cells appeared in the vaccine-treated group. Conclusion The results of our study have demonstrated that the human interleukin-2 surface-modified MB49 bladder cancer cell vaccine induced specific antitumor immunity and was efficient against metastatic bladder cancer.
ISSN:0090-4295
1527-9995
DOI:10.1016/j.urology.2011.04.044